lantus- insulin glargin injection, solution lantus- insulin glargine injection, solution
physicians total care, inc. - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine 100 [iu] in 1 ml - lantus is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. important limitations of use: - lantus is not recommended for the treatment of diabetic ketoacidosis. intravenous short-acting insulin is the preferred treatment for this condition. lantus is contraindicated in patients with hypersensitivity to lantus or one of its excipients. enter section text here pregnancy category c: subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and himalayan rabbits. insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0.36 mg/kg/day, which is approximately 7 times the recommended human subcutaneous starting dose of 10 units/day (0.008 mg/kg/day), based on mg/m2 . in rabbits, doses of 0.072 mg/kg/day, which is approximately 2 times the recommended human subcutaneous starting dose of 10 units/day
humulin r biosynthetic human neutral insulin 100iu/ml injection multidose cartridge
eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; metacresol; hydrochloric acid; glycerol - other conditions: refrigerate - do not freeze. indications: for the treatment of insulin dependent diabetic patients.
humulin r insulin 100iu/ml injection vial
eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, solution - excipient ingredients: metacresol; glycerol; water for injections; hydrochloric acid; sodium hydroxide - indications as at 05 feb 2002 : humulin is indicated for the treatment of insulin - dependant diabetic patients.
hypurin neutral insulin
healthcare distributors ltd - insulin, human, recombinant dna origin 100 iu/ml - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 iu/ml
mixtard 50/50 (human)
novo nordisk pharmaceuticals ltd - insulin, human, recombinant dna origin 50 iu/ml; isophane insulin, human 50 iu/ml - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 50 iu/ml isophane insulin, human 50 iu/ml
velosulin (human)
novo nordisk pharmaceuticals ltd - insulin, human, recombinant dna origin 100 iu/ml - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 iu/ml
exubera- insulin human exubera- insulin human aerosol, powder
pfizer inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - kit - 1 mg - exubera is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. exubera has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. in patients with type 1 diabetes, exubera should be used in regimens that include a longer-acting insulin. in patients with type 2 diabetes, exubera can be used as monotherapy or in combination with oral agents or longer-acting insulins. exubera is contraindicated in patients hypersensitive to exubera or one of its excipients. exubera is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting exubera therapy. if a patient starts or resumes smoking, exubera must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see clinical pharmacology, special populations, smoking). the safety and efficacy of exube
novomix 30 flexpen 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection syringe
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc; metacresol; water for injections; glycerol; sodium chloride; protamine sulfate; sodium hydroxide; dibasic sodium phosphate dihydrate; phenol - treatment of diabetes mellitus.
novomix 30 penfill 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection cartridge
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.
insugen-r (regular) insulin injection soluble 100iuml
biocon sdn bhd - insulin human -